Allegro Diagnostics plans to debut next year its BronchoGen genomic lung-cancer assay, the test maker's first commercially available product.
The test is designed to detect a gene-expression signature from benign airway cells and indicate the presence of malignancy remotely in the lung by relying on the "common molecular response" that occurs throughout the respiratory tract in current and former smokers with lung cancer.
News of the impending launch was buried in a press release yesterday announcing Allegro's exclusive licensing agreement with Boston University and the University of Utah Foundation for IP related to the assay.
According to Allegro, BronchoGen "has the potential" to be used with standard bronchoscopy procedures "to provide additional critical diagnostic information to support more rapid diagnosis and treatment."
[Image] Got a tip? Click my byline above to send it along or submit it as a comment below. Follow my headlines on Twitter or subscribe to my RSS feed. Learn more about me or become a source via Linkedin, where all conversations are confidential.